The FDA approved AMX0035 (Relyvrio) for amyotrophic lateral sclerosis (ALS) Thursday; new research suggests looking at microbes and fungi within cancer tumors; US suicides increased in 2021 following a 2-year decrease in deaths by suicide.
The FDA approved experimental drug AMX0035 (Relyvrio) for amyotrophic lateral sclerosis (ALS) Thursday, The Washington Post reported. AMX0035 was developed to slow the effects of ALS by protecting nerve cells in the brain and spinal cord damaged by the neurological condition. The approval was granted despite it being a much-debated drug with questions about its efficacy. However, some individuals living with ALS said a treatment with any amount of efficacy is important, as this was the first approval for an ALS treatment in 5 years.
New research suggested looking at microbes and fungi within cancer tumors rather than treating tumors as if they are sterile, The New York Times reported. A team of researchers detected bacteria living in pancreatic tumors in 2017, prompting further research on how a species of bacteria could block a chemotherapy drug from working and later finding bacteria in tumors of 7 types of cancer. Using these findings, another team of researchers found that a small percentage of DNA fragments in 32 types of cancer belonged to bacteria rather than humans. The 2 research teams collaborated and found that, in 35 different types of cancer, all of them contained fungi and each had a distinctive combination of fungal species.
Following a 2-year decrease in suicides in 2019 and 2020, US suicides have risen again, with experts saying rates are returning to prepandemic levels, The Wall Street Journal reported. This finding is based on data from the National Center for Health Statistics. The report stated 47,646 Americans died by suicide in 2021, reflecting a nearly 4% increase compared with the still high count of 45,979 deaths by suicide in 2020. It also said men aged between 15 and 24 years experienced the sharpest increase with an 8% rise in 2021. Notably, despite the onset of the COVID-19 pandemic, suicide rates did not markedly increase in 2020.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More